We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




First High-Throughput Imaging Platform for Predicting Kidney Toxicity of Chemicals

By LabMedica International staff writers
Posted on 27 Jan 2016
Print article
Image: The “cellXpress” automated imaging analysis software enables to efficiently and accurately detect cellular responses (reflected in green) to nephrotoxic compounds (Photo courtesy of Agency for Science, Technology and Research (Singapore)).
Image: The “cellXpress” automated imaging analysis software enables to efficiently and accurately detect cellular responses (reflected in green) to nephrotoxic compounds (Photo courtesy of Agency for Science, Technology and Research (Singapore)).
Researchers have developed a high-throughput platform of automated cellular imaging that efficiently and accurately predicts renal toxicity of chemical compounds without animal testing, providing an improved approach to development of safer medicines and other chemical products.

Researchers at A*STAR’s (Agency for Science, Technology and Research) Bioinformatics Institute (BII; Singapore) and Institute of Bioengineering and Nanotechnology (IBN; Singapore) developed the platform based on an approach combining cell culture, imaging, and computational methods. The system could prove invaluable to pharmaceutical companies as well as companies in food, nutrition, cosmetics, consumer care, environmental, and other chemical-dependent sectors.

About 20% of hospital or community acquired cases of acute kidney injury can be attributed to nephrotoxic drugs. Currently there is no accurate method for screening large numbers of potentially nephrotoxic compounds with diverse chemical structures. Existing approaches for predicting compound toxicity include animal testing, which involves ethical issues, high costs, and long turnaround times that result in low throughput, making it unsuitable for screening the increasing numbers of potentially nephrotoxic compounds used in products. Animal testing may also result in poor prediction of human toxicity due to interspecies differences. Other methods of nephrotoxicity screening are also slow, laborious, and costly, or may require prior knowledge of compound chemical structure or mechanism of action.

The researchers have been developing cell-based screening methods that address this critical need, particularly as animal testing bans for cosmetics have been implemented in the EU, Norway, India, and Israel, with many more countries expected to follow suit. They recently reported the first and only cell-based renal screening platforms that can predict nephrotoxicity with high accuracy. Improving on this, they have now developed an imaging-based method that can be used to test much larger numbers of compounds.

Dr. Lit-Hsin Loo, study coauthor and BII principal investigator, said “By automatically analyzing more than 25,000 microscopy images of cells treated with different compounds, we were able to identify phenotypic signatures of kidney cells that can be used to predict the in vivo toxicity of compounds with diverse structures and mechanisms, with a validated accuracy of 80%–90%.”

In this study, over 2 million individual cells were screened for reactions to over 40 different chemical compounds, including antibiotics, antivirals, chemotherapy drugs, and industrial and agricultural chemicals. Analysis was performed using “cellXpress”, an automated image analysis software developed by Dr. Loo’s team.

Coauthor Dr. Daniele Zink, IBN team leader and principal research scientist, added, “This novel software platform reduces the reliance on existing laborious and time-consuming methods currently available for testing of nephrotoxic compounds, enabling much faster predictions. We will continue to work together to improve and further validate the use of this approach, and hope that our work will help to make products safer for consumers and patients.”

The study, by Su R et al, was published online ahead of print November 27, 2015, in the journal Archives of Toxicology.

Related Links:

Institute of Bioengineering and Nanotechnology at A*STAR
Bioinformatics Institute at A*STAR


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.